4.3 Article

Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose

期刊

BLOOD PURIFICATION
卷 41, 期 1-3, 页码 11-17

出版社

KARGER
DOI: 10.1159/000439581

关键词

Dialysis; Continuous renal replacement therapy; Catheters; Femoral vein; Intensive care

资金

  1. National Health and Medical Research Council (NHMRC) of Australia [352550]
  2. Health Research Council (HRC) of New Zealand [06-357]
  3. Australian National Health and Medical Research Council
  4. Roche
  5. Gambro
  6. Karolinska Institutet
  7. Servier
  8. Novartis
  9. Eisai
  10. Merck
  11. Sharp Dohme
  12. Pfizer Australia
  13. Fresenius Kabi Deutschland GmbH
  14. Sanofi Aventis

向作者/读者索取更多资源

Aims: The study aims to describe the use of dialysis catheters in critically ill patients treated with continuous renal replacement therapy (CRRT) and to study the impact of femoral versus non-femoral access on CRRT dose. Methods: Statistical analysis and predictive modelling of data from the Randomized Evaluation of Normal vs. Augmented Level renal replacement therapy trial. Results: The femoral vein was the first access site in 937 (67%) of 1,399 patients. These patients had higher Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores (p = 0.009) and lower pH (p < 0.001) but similar mortality to patients with non-femoral access (44 vs. 45%; p = 0.63). Lower body weight was independently associated with femoral access placement (OR 0.97, 95% CI 0.96-0.98). Femoral access was associated with a 1.03% lower CRRT dose (p = 0.05), but a 4.20% higher dose was achieved with 13.5 Fr catheters (p = 0.03). Conclusions: Femoral access was preferred in lighter and sicker patients. Catheter gauge had greater impact than catheter site in CRRT dose delivery. Video Journal Club Cappuccino with Claudio Ronco at http://www.karger.com/?doi=439581. (C) 2015 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据